Your session is about to expire
← Back to Search
Corticosteroid
BRVO 1 mg dose triamcinolone acetonide for Macular Edema (SCORE Trial)
Phase 3
Waitlist Available
Research Sponsored by The Emmes Company, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 12 months
Awards & highlights
Summary
The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
Eligible Conditions
- Macular Edema
- Retinal Vein Occlusion
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline to 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit
Trial Design
6Treatment groups
Active Control
Group I: BRVO 1 mg dose triamcinolone acetonideActive Control1 Intervention
Group II: BRVO 4 mg dose triamcinolone acetonideActive Control1 Intervention
Group III: CRVO 1 mg dose triamcinolone acetonideActive Control1 Intervention
Group IV: CRVO ObservationActive Control1 Intervention
Group V: CRVO 4 mg dose triamcinolone acetonideActive Control1 Intervention
Group VI: BRVO standard careActive Control1 Intervention
Find a Location
Who is running the clinical trial?
The Emmes Company, LLCLead Sponsor
147 Previous Clinical Trials
1,051,502 Total Patients Enrolled
5 Trials studying Macular Edema
126 Patients Enrolled for Macular Edema
National Eye Institute (NEI)NIH
551 Previous Clinical Trials
1,406,231 Total Patients Enrolled
44 Trials studying Macular Edema
8,494 Patients Enrolled for Macular Edema
AllerganIndustry Sponsor
781 Previous Clinical Trials
275,972 Total Patients Enrolled
57 Trials studying Macular Edema
10,737 Patients Enrolled for Macular Edema
Share this study with friends
Copy Link
Messenger